Compounds and Methods for Reducing KCNT1 Expression
AssigneeIonis Pharmaceuticals, Inc.
InventorPaymaan Jafar-nejad
Life of this patent
Estimating the term…
Loading patent…
AssigneeIonis Pharmaceuticals, Inc.
InventorPaymaan Jafar-nejad
Estimating the term…
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of KCNT1 RNA in a cell or subject, and in certain instances reducing the amount of KCNT1 protein in a cell or subject. These compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurological condition. Such symptoms and hallmarks include seizures, encephalopathy, and behavioral abnormalities. Non-limiting examples of neurological conditions that benefit from these compounds, methods, and pharmaceutical compositions are epilepsy of infancy with migrating focal seizures (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), West syndrome, and Ohtahara syndrome.
An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to an equal length portion of a KCNT1 nucleic acid, and wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.
An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of SEQ ID NOs:
An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides and having a nucleobase sequence comprising at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 contiguous nucleobases complementary to:
An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides and having a nucleobase sequence comprising at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 contiguous nucleobases complementary to:
An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases SEQ ID NOs:
An oligomeric compound comprising a modified oligonucleotide according to the following formula:
An oligomeric compound comprising a modified oligonucleotide according to the following formula:
An oligomeric compound comprising a modified oligonucleotide according to the following formula:
An oligomeric compound comprising a modified oligonucleotide according to the following formula:
An oligomeric compound comprising a modified oligonucleotide according to the following formula:
An oligomeric compound comprising a modified oligonucleotide according to the following formula:
An oligomeric compound comprising a modified oligonucleotide according to the following formula:
An oligomeric compound comprising a modified oligonucleotide according to the following formula:
An oligomeric compound comprising a modified oligonucleotide according to the following formula:
An oligomeric compound comprising a modified oligonucleotide according to the following formula:
The modified oligonucleotide of claim 52, which is the sodium salt or the potassium salt.
A modified oligonucleotide according to the following chemical structure:
Dependencies are inferred from the claim text.